# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Gain Therapeutics announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a pub...
Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre...